Skip to content
Search

Latest Stories

PDA campaign calls for workplace equality for pharmacists with disabilities

PDA campaign calls for workplace equality for pharmacists with disabilities

Pharmacists' Defence Association (PDA) has launched a compelling campaign, 'Standing up for Sitting Down', aimed at fostering workplace dignity and equality for pharmacists with disabilities across the UK.

A recent survey conducted by the PDA revealed shocking statistics: more than half of respondents reported experiencing disability discrimination at their workplaces.

Of these, a significant majority—over 60 per cent —pointed fingers at their managers, while 48 per cent cited discrimination from their colleagues.


In highlighting the significance of an inclusive work environment, the PDA underscored that supportive workplaces not only enhance pharmacist satisfaction but also bolster their productivity.

An anonymous PDA member shared their positive experience, highlighting how colleague assistance with daily tasks contributes to their job satisfaction.

“I am very fortunate at work as my colleagues are always helpful to me. Particularly with opening heavy doors and running errands.”

However, many respondents talked about the discrimination they faced from managers, colleagues and patients along with the impact it has had on them.

Some respondents described being “made to feel guilty” for using the bathroom, feeling “let down, discarded and forgotten”, and the “lack of support and understanding added to my mental and physical stress.”

Despite these positive notes, many respondents shared harrowing experiences of discrimination.

Some recounted feeling guilt-tripped for using basic facilities, feeling neglected and forgotten, and enduring additional mental and physical stress due to a lack of support.

In response, the PDA has issued a fervent call to action for employers across the country.

They advocate for collaborative efforts to create workplaces that uphold the dignity of pharmacists with disabilities and chronic health conditions.

Key recommendations include the implementation of robust anti-discrimination policies, comprehensive equality training, and the promotion of a cooperative and flexible work culture.

The campaign emphasises the importance of appreciating and embracing diversity within the pharmacy profession.

One member succinctly captured the sentiment: "Disabilities aren’t a crime or a stigma," underscoring the need for workplaces that celebrate and respect individuals of all backgrounds.

By championing these initiatives, the PDA aims to ensure that pharmacists with disabilities can contribute fully and thrive within their workplaces, free from discrimination and with equal opportunities for professional growth and success.

More For You

Pharmacist Support calls for birthday donations to meet rising demand for mental health services

More and more pharmacy professionals are reaching out for help, said Danielle Hunt.

Pharmacist Support's birthday appeal: Donate to address growing mental health demand

Pharmacist Support – the independent charity dedicated to the pharmacy profession – is celebrating 184 years of service with the launch of a special birthday donations appeal.

On 15 April, the charity is urging individuals and organisations across the sector to support its campaign to raise vital funds to meet the increasing demand for its mental health and wellbeing services.

Keep ReadingShow less
Prostate cancer: At-home saliva test could save NHS £500 million annually

PRS saliva test can identify prostate cancer that was missed by an MRI scan

Photo credit: gettyimages

Prostate cancer: Spit test better than blood test in spotting men at highest risk

A simple at-home spit test could help detect prostate cancer earlier, saving the NHS around £500 million a year, according to new research published in the New England Journal of Medicine.

Funded by the National Institute for Health and Care Research (NIHR), the study found that the DNA-based saliva test was more accurate than the current prostate-specific antigen (PSA) blood test in identifying men at risk of developing prostate cancer.

Keep ReadingShow less
RPS launches innovative new learning resources for members

With RPS Learn, pharmacists can develop a new skill or improve their understanding of practice or a clinical topic.

Gettyimages

RPS launches new learning resources to boost career development for members

The Royal Pharmaceutical Society (RPS) has launched a new online learning platform designed to support the practice, development and career advancement of its members.

The new platform, called RPS Learn, offers a diverse range of bite-size learning content, available on-demand, catering to all levels — from introductory to advanced and specialist —combining new content with RPS's renowned expertise in education and training to achieve excellence for learners.

Keep ReadingShow less
NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less